Email us at [email protected] love to talk to you
This is a ready-to-use formulation, meaning healthcare providers do not need to perform any additional reconstitution before administration
After announcing the state would initiate coverage of GLP-1s to combat obesity in September 2022 as part of their state employee health plan, the state reversed course and in January 2025 announced it was opting to end that coverage beginning July 1, 2025
This can damage metabolic health and lead to complications like heart disease and type 2 diabetes, as well as increase the risk of falls
Given that obesity and adiposity embed an obesogenic epigenetic memory and are linked to accelerated epigenetic aging 8,9,10 , there is growing interest in whether semaglutides metabolic effects might slow or reverse aspects of biological aging
This is a clinical decision - the platform cannot pre-approve or guarantee that a prescription will be issued